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Febrile neutropenia (FN) causes significant morbidity and mortality in patients receiving cytotoxic chemotherapy and can lead to
reduced chemotherapy dose intensity and increased overall treatment costs. Antibiotic prophylaxis reduces the incidence of FN.
Recent research and meta-analyses confirm that prophylactic fluoroquinolones decrease FN and infection-related mortality in patients
with acute leukaemia and those receiving high-dose chemotherapy. Fluoroquinolone prophylaxis also lowers the incidence of FN and
all-cause mortality following the first cycle of myelosuppressive chemotherapy for solid tumours. Levofloxacin has been the agent
studied most thoroughly in this context. Although there is no convincing evidence that colonisation of individuals with resistant
organisms due to antibiotic prophylaxis increases FN or mortality, such concerns must be taken seriously and the use of prophylaxis
should be limited responsibly for patients with the greatest chance of benefit. Fluoroquinolone prophylaxis is well tolerated and cost-
effective and should be offered to patients receiving chemotherapy for haematological malignancies and high-dose chemotherapy for
solid tumours in which prolonged (47 days) neutropenia is expected. It should also be considered for those receiving chemotherapy
for solid tumours and lymphomas during the first cycle of chemotherapy when grade 4 neutropenia is anticipated.
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For many years, controversy has surrounded the use of
prophylactic antibiotics following chemotherapy for malignant
diseases. Although effective, the toxicity of the trimethoprim–
sulfamethoxazole combination led to a decline in its use, and
raised questions about the prophylaxis of febrile neutropenia (FN)
in general, particularly as mortality from FN was diminishing.
However, as discussed elsewhere in this supplement (Cameron,
2009; Krell and Jones, 2009; Kelly and Wheatley, 2009; Jones and
Leonard, 2009), data have emerged highlighting a range of risks
associated with FN, including the adverse effects of consequent
chemotherapy dose reduction and delays, FN morbidity, and
mortality rates reaching 4–6%, as well as the costs of managing the
condition (Trueman, 2009; Van de Wetering et al, 2005).
Furthermore, some of the newer, effective chemotherapy agents,
such as docetaxel and vinorelbine, are especially prone to causing
FN (Aapro et al, 2006).
The fluoroquinolones, introduced in the 1980s, have trans-
formed this field, becoming the most commonly used prophylactic
antibacterial agents in neutropenic patients because of their broad
antimicrobial spectrum, preservation of anaerobic gut flora
(Walker, 1999), systemic bactericidal activity (Reeves, 1986), good
tolerability and lack of myelosuppression (Del Favero and
Menichetti, 1993).
In the past 5 years, major randomised trials and meta-analyses
have led to significant progress in our understanding of the
efficacy of fluoroquinolone prophylaxis, and the categories of
patients (and chemotherapy regimens) associated with the greatest
risk of FN, and hence those most likely to benefit from
prophylactic treatment. The use of granulocyte colony-stimulating
factors, with or without antibiotics, in the prophylaxis of FN is
described in this supplement by Kelly and Wheatley. Our review
summarises the evidence supporting the use of prophylactic
antibiotics following chemotherapy and highlights the situations in
which the gains are likely to be greatest.
RECENT RESEARCH
Two large, investigator-led, randomised controlled trials published in
2005 provide firm evidence of the efficacy of fluoroquinolone
prophylaxis in two distinct contexts: hospitalised patients expecting
prolonged neutropenia, and patients receiving cyclical, mainly out-
patient-based, chemotherapy causing neutropenia of a short duration.
Hospitalised patients expecting prolonged neutropenia
Bucaneve et al (2005) reported findings from a double-blind,
placebo-controlled trial of 760 hospitalised adult patients in
whom chemotherapy-induced neutropenia (below 1000 neutro-
phils per mm
3) was expected to last longer than 7 days. The trial
included patients receiving chemotherapy for acute leukaemia,
lymphomas or solid tumours. They were randomised to receive
oral levofloxacin (500mg daily) or placebo from the start of
chemotherapy until the resolution of neutropenia. Intention-to-
treat analysis showed a lower incidence of fever in patients
receiving levofloxacin compared with the placebo group (65 vs
85%, respectively, P¼0.001). Mortality was lower in the levo-
floxacin group but the study was not powered to prove this.
Cyclical, mainly outpatient-based, chemotherapy causing
neutropenia of short duration
In the UK Significant (simple investigation in neutropenic
individuals of the frequency of infection after chemotherapy þ/ 
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solid tumours (predominantly breast, lung and testicular) or
lymphoma, who were at risk of temporary, severe neutropenia
(below 500neutrophils per mm
3) were randomised to receive
either levofloxacin (500mg daily) or placebo for 7 days during the
expected neutropenic period in up to six cycles of chemotherapy.
A significant reduction in febrile episodes and hospitalisation for
treatment of bacterial infection was documented in the levoflox-
acin group during all cycles of treatment. Thirty-day mortality was
lower in the levofloxacin group (1.5%) compared with the placebo
group (2.3%), but the difference did not reach statistical
significance (Cullen et al, 2005; Leibovici et al, 2006). The
Significant Trial was by far the largest study looking specifically
at antibiotic prophylaxis of FN in patients with solid tumours and
lymphoma receiving moderately myelosuppressive chemotherapy,
and it resolved the efficacy question for this group of patients.
META-ANALYSES EXAMINING MORTALITY
As death from FN is relatively rare, meta-analyses are necessary to
examine the effects of interventions on mortality. Gafter-Gvili et al
(2005) undertook a meta-analysis of trials comparing prophylactic
antibiotic therapy (fluoroquinolone-based and other regimens)
with placebo or no intervention in patients receiving chemother-
apy. They analysed 95 randomised controlled trials conducted
between 1973 and 2004 involving 9283 patients. The primary
outcome was all-cause mortality, and secondary outcomes
included infection-related death, febrile episodes, bacteraemia,
adverse events and emergence of bacterial resistance. The meta-
analysis showed a statistically significant reduction in all-cause
mortality of 34% in patients receiving prophylaxis compared with
placebo or no intervention, and a 45% reduction in mortality in
those receiving fluoroquinolones. Although the relative risk of
death did not differ between haematological malignancies and
solid tumours in this meta-analysis, the number of solid tumours
was much smaller. Consequently, the meta-analysis has been
updated (Leibovici et al, 2006) to include data from GIMEMA
(Gruppo Italiano Malattie Ematologiche Maligne dell’Adulto)
(Bucaneve et al, 2005) and the Significant Trial (Cullen et al,
2005). Among patients with acute leukaemia, who had undergone
bone marrow transplantation, the relative risk of death with
fluoroquinolone prophylaxis was 0.67 (0.55–0.83) – a one-third
reduction compared with the control group, which did not receive
prophylaxis. Among patients with solid tumours and lymphomas,
fluoroquinolone prophylaxis had a significant impact on all-cause
mortality during the first cycle of chemotherapy, with a relative
risk of 0.48 (0.26–0.88), compared with controls.
VARIABLES THAT AFFECT FN RISK AND
PROPHYLACTIC EFFICACY
The effect of cycle number on the risk of FN has been known but
under-appreciated for some years. Studies in small-cell lung cancer
and breast cancer have shown that the risk of FN is much greater
following the first cycle of chemotherapy compared with later
cycles (Holmes et al, 2002; Timmer-Bonte et al, 2005; Vogel et al,
2005). This finding has been confirmed in surveys of larger
numbers of patients with lymphoma (Lyman and Delgado, 2003)
and multiple tumour types (Crawford et al, 2004). There are several
possible explanations for the first-cycle effect. For example,
neutropenia that is not accurately predictable for a given patient
may be severe in the first cycle, then reduced when subsequent
cycles are subject to secondary modification, such as dose
reduction. Alternatively, the cytoreductive effects of the first
chemotherapy cycle may enable resolution of a cancer-related
focus of infection (e.g., beyond an obstructed airway in a patient
with lung cancer) or lead to an improvement in performance status.
Other variables that predict increased rate of FN are discussed
elsewhere in this supplement (Kelly and Wheatley, 2009).
RATIONAL SELECTION OF PATIENTS FOR
ANTIBACTERIAL PROPHYLAXIS
A second publication from the Significant Trial examined
chemotherapy cycle effects and other variables that might predict
increased efficacy of levofloxacin prophylaxis (Cullen et al, 2007). It
showed that the incidence of FN was 8% in first cycles but only 3.3%
per cycle thereafter. In addition, prophylaxis was more effective in
first cycles (odds ratio 0.42, Po0.001) than in later cycles (odds ratio
0.78). However, FN in cycle 1 predicted a much higher risk of
subsequent FN and a trend towards continued prophylactic efficacy
in later cycles (Figure 1). Among the cancers studied, the rate of FN
was greatest for testicular cancer (27.9%), followed by small-cell lung
cancer (17.3%), and lowest for breast cancer (11.5%). Prophylactic
efficacy was consistent despite differences in age, sex, performance
status, treatment context (adjuvant or advanced) and disease type
(except possibly non-Hodgkin’s lymphoma).
In the light of the pressure to limit antibacterial use (for reasons
discussed below), the data on cycle effects support the practice of
offering prophylactic levofloxacin in the first cycle of myelosuppres-
sive cancer chemotherapy, and in subsequent cycles only if there has
been a fever in cycle 1. These data also show that prophylactic
levofloxacin is effective regardless of the patient’s age or performance
status, or the type of solid tumour (Cullen et al, 2007).
CONCERNS ABOUT ANTIBIOTIC PROPHYLAXIS
Treatment cost
Bucaneve et al (2005) showed that five patients undergoing
chemotherapy for cancer needed to be treated with oral
levofloxacin to prevent one episode of FN. The average length of
prophylaxis in the study was 14 days for patients receiving
chemotherapy for solid tumour or lymphoma, and 27 days for
patients with acute leukaemia. A 7-day course of levofloxacin in
the UK costs d18.10 (BNF, 2009). It therefore costs only d181.00
and d349.07, respectively, to prevent an episode of FN in these two
groups. The Significant Trial did not directly address the economic
aspects of prophylaxis. However, analysis shows that 23 patients
needed to be treated with levofloxacin to prevent one episode of
FN (Table 1), and that the cost of prophylaxis for 23 patients for
one cycle of chemotherapy is approximately d416.30 (Cullen et al,
2005). The cost of managing one episode of FN in the UK has been
estimated as d4064.84 (Holmes et al, 2004), suggesting that
antibiotic prophylaxis is cost-effective in these patient groups.
Antibiotic resistance
The main concern over the use of prophylactic antibiotics remains
the emergence of antibiotic resistance, and its implications both
for the individual patient and at ward level.
Placebo
Levofloxacin
No FE cycle 1 FE on cycle 1
2.2
1861
3.1
710
2.5
1814
2.6
667
11.5
148
15.5
58 21
9.5
47
10.6
3.5 8.0 Cycle 1 FN rate %
Cycle 2 total given
Cycle 2 FN rate %
Cycle 3 – 6 total given
Cycle 3 – 6 FN rate %
Figure 1 FN rate per cycle and impact on later events in the Significant
Trial (Cullen et al, 2007). FE, Febrile episode.
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can cause colonisation of individual patients with resistant
organisms, but the clinical relevance of this is unclear. Bucaneve
et al (2005) observed a non-significant increase in the incidence of
levofloxacin-resistant Gram-negative bacteraemia among patients
receiving levofloxacin, but this did not affect outcomes such as
infection-related morbidity or mortality. Gafter-Gvili et al (2005)
found that the risk of developing fluoroquinolone resistance did
not increase significantly secondary to prophylaxis, and that there
was a low incidence of infections caused by resistant bacteria in
patients who had received prophylaxis.
There have been several reports of the emergence of fluoroqui-
nolone-resistant bacteria in units that practise fluoroquinolone-
based prophylaxis (Razonable et al, 2002; Kern et al, 2005).
However, there is no convincing evidence that patients have
suffered adverse outcomes as a result. Kern et al (2005) found that
after fluoroquinolone prophylaxis had been in use for 10 years,
there was an increase in the number of cancer patients colonised
or infected with fluoroquinolone-resistant Escherichia coli. The
practice of prophylaxis was stopped for 6 months in the unit, and a
significant increase in the incidence of Gram-negative bacteraemia
was found in patients with cancer, accompanied by a decrease in
the proportion of fluoroquinolone resistance in E coli bacteraemia.
After the resumption of prophylaxis, an increase in the proportion
of in vitro fluoroquinolone resistance in E coli bacteraemia was
observed, but the incidence of all Gram-negative bacteraemia was
reduced to pre-discontinuation levels. The authors suggest that the
rate of resistance in their unit is a poor indicator of the potential
clinical benefits associated with fluoroquinolone prophylaxis in
patients with cancer.
NCCN GUIDELINES
In 2008, the US National Comprehensive Cancer Network
published guidelines on the prevention and treatment of cancer-
related infections (Segal et al, 2008). It recommends prophylactic
fluoroquinolones for high-risk and intermediate-risk groups,
which largely comprise patients receiving high-dose chemotherapy
and those with haematological malignancy in which the antici-
pated duration of neutropenia is longer than 7 days. For most solid
tumours undergoing standard outpatient cyclical chemotherapy, in
which the anticipated duration of neutropenia is less than 7 days,
prophylactic fluoroquinolones are not recommended, because of
the risk of microbial resistance. However, even in the latter
circumstances, we believe that when grade 4 neutropenia is
expected (e.g., etoposide-containing regimens for testicular and
small-cell lung cancers, and regimens containing docetaxel,
vinorelbine or doxorubicin), in which the risk of FN is very high,
fluoroquinolones should be considered, particularly in the first
cycle.
CONCLUSION
There is now convincing evidence that antibiotic prophylaxis
reduces the incidence of FN and mortality in patients receiving
cytotoxic chemotherapy for acute leukaemia and for patients with
solid tumours and lymphoma receiving high-dose chemotherapy
(Segal et al, 2008). Therefore, we would argue that antibiotic
prophylaxis should be offered routinely to these groups of patients.
Fluoroquinolone prophylaxis also significantly reduces FN in
patients with solid tumours or lymphoma who are undergoing
cyclical standard-dose myelosuppressive chemotherapy (Cullen
et al, 2005). A significant impact on all-cause 30-day mortality was
also shown in this group (Leibovici et al, 2006). We believe
prophylaxis is indicated during the first cycle of chemotherapy in
which there is an expectation of grade 4 neutropenia (below
500 neutrophils per mm
3).
Fluoroquinolones are the most effective agents for prophylaxis
of FN, and are cost effective and well tolerated (Reeves, 1986; Del
Favero and Menichetti, 1993; Walker, 1999). When choosing
between the fluoroquinolones, clinicians should take into account
the patterns of pathogens and resistance in their patient
population, and remember that, compared with ciprofloxacin,
levofloxacin has additional activity against Gram-positive organ-
isms but less anti-pseudomonal activity (MacGowan et al, 1999;
Montanari et al, 1999). Compliance is a major concern when
considering oral prophylactic therapy, so once-daily levofloxacin
may have an advantage in this regard.
The main concern relating to the prophylactic use of antibiotics
remains the development of resistance. Although it is established
that fluoroquinolone prophylaxis can result in increased
fluoroquinolone resistance in treatment centres, there is little
evidence of a resultant increase in FN or infection-related
mortality (Bucaneve et al, 2005).
There are also important ethical concerns about withholding a
proven treatment from current patients for the sake of an
unquantified benefit to patients in the future.
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Table 1 Levofloxacin vs placebo to prevent infection after chemotherapy in patients with solid tumours or lymphoma (Cullen et al, 2005)
Outcomes Levofloxacin (%) Placebo (%) RRR (95% CI) P-value NNT (CI)
In first cycle
Febrile episode 3.5 7.9 56% (32–72) o0.001 23 (15–46)
Probable infection 14 19 28% (10–43) 19 (11–58)
Hospitalisation 6.7 10 36% (10–54) 28 (16–109)
In any cycle
Febrile episode 11 15 29% (8.1–45) 0.01 23 (13–91)
Probable infection 34 41 18% (6.3–27) 14 (9–41)
Hospitalisation 16 22 27% (9.9–41) 0.004 18 (11–52)
Severe infection or death 1.0 2.0 50% (-14–78) NS
RRR¼Relative risk reduction; NNT¼Number needed to treat; NS¼Not significant.
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